Table 3 Use of analgesic/antipyretic medication on symptoms following COVID-19 vaccination in clinical trials.
From: Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination
Vaccine | Trial | Analgesics/antipyretics | ||
|---|---|---|---|---|
Treatment/prophylaxis | Use (% patients) | Effect on vaccine reactogenicity | ||
BNT162b2 (Pfizer/BioNTech) | Phase 1 N = 9057 | Treatment: antipyretic/pain medication following vaccination (not specified) | Use of antipyretic/pain medication increased with increasing dose level and number of doses administered in both age groups (data not shown) | — |
Phase 2/3 N = 8,183 (reactogenicity subset)37 | Aged 16–55 years Dose 1: 28% versus 14% for placebo Dose 2: 45% versus 13% for placebo Aged >55 years Dose 1: 20% versus 12% for placebo Dose 2: 38% versus 10% for placebo | — | ||
AZD1222 (Oxford/AZ) | Phase 1/2 N = 54356 | Prophylaxis: acetaminophen (1 g) before vaccination and continued every 6 h for 24 h | 10.3%* | Acetaminophen versus no acetaminophen prophylaxis Local AEs • Injection-site pain (50% vs 67%) • Tenderness (77% vs 83%) Systemic AEs • Fatigue (71% vs 70%) • Headache (61% vs 68%) • Muscle ache (48% vs 60%) • Malaise (48% vs 62%) • Chills (27% vs 56%) • Feeling feverish (36% vs 51%) |
Ad26.COV2.S (Janssen/J&J) | Treatment: antipyretic/pain medication following vaccination (not specified) | All: 19.9% versus 5.7% for placebo Aged 18–59 years: 26.4% versus 6.0% for placebo Aged ≥60 years: 9.8% versus 5.1% for placebo | — | |
